A Day Up For Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ) shot up at $4.62, representing a gain of 28.7%. On Mon 25 Nov 19, HEPA:NASDAQ touched a New 2-Week High of $3.59. The stock got featured on our News Catalysts scanner on Thu 21 Nov 19 at 08:55 AM in the 'BIOTECH' category. From Tue 05 Nov 19, the stock recorded 42.86% Up Days and 33.33% Green Days

The stock spiked on Thu 17 Oct 19 at $5.59 with a volume of 37M+.

About Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ)

ContraVir Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. The company focuses on developing two novel oral compounds to treat HBV infection. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. TXL is a nucleotide pro-drug of tenofovir that inhibits hepatitis B viral replication and targets the liver, the reservoir for the hepatitis B virus.